Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a neutral rating and issued a $1.00 target price on shares of Cytosorbents in a report on Friday, March 15th.

Cytosorbents Trading Up 7.4 %

NASDAQ:CTSO opened at $0.88 on Thursday. Cytosorbents has a 52 week low of $0.78 and a 52 week high of $4.29. The firm’s fifty day moving average is $0.91 and its 200-day moving average is $1.13. The firm has a market cap of $47.79 million, a P/E ratio of -1.38 and a beta of 0.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The business had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. Equities analysts expect that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC grew its stake in shares of Cytosorbents by 84.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after buying an additional 16,598 shares during the period. Skylands Capital LLC grew its stake in Cytosorbents by 5.4% in the third quarter. Skylands Capital LLC now owns 2,944,670 shares of the medical research company’s stock valued at $5,536,000 after acquiring an additional 151,200 shares during the period. Raymond James & Associates acquired a new stake in Cytosorbents in the fourth quarter valued at approximately $56,000. Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.1% during the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its position in shares of Cytosorbents by 19.9% during the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares during the period. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.